Copper-Aspirin Complex Inhibits Cyclooxygenase-2 More Selectively than Aspirin

Copper-aspirin complex inhibits cyclooxygenase-2 more selectively than aspirin.

The antiinflammatory effects of the copper-aspirin complex (Cu-Asp) were more potent than that of Asp in rats or mice with fewer classic adverse effects. The aim of this study was to determine the cause by evaluating Cu-Asp selective inhibition on cyclooxygenases (COX). COX-1 inhibition was evaluated based on 6-keto-prostaglandin F(1alpha) (6-keto-PGF(1alpha)) in an endothelial cell model, and ...

Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics.

Asthma is characterized by chronic airway inflammation resulting from overproduction of pro-inflammatory mediators, such as leukotrienes (LT). The authors questioned the biosynthetic capacity of asthmatic patients for lipoxins (LX) and 15-epimer lipoxins (15-epi-LX), endogenous regulators of inflammatory responses that inhibit pro-inflammatory events. Levels of LXA4, 15-epi-LXA4 and LTC4 were d...

Cyclooxygenase-2 inhibitors in aspirin-sensitive asthma.

A Dermal Aspirin Preparation Selectively Inhibits Platelet Cyclooxygenase and Preserves Prostacyclin Biosynthesis

cause gastrointestinal toxicity. We examined the skin as a novel route for continuous low-dose aspirin administration and selective inhibition of platelet cyclooxygenase in humans. Methods and Results. Aspirin 250 or 750 mg/d for 10 days induced a dose-dependent inhibition of serum thromboxane (TX) B2. At the highest dose, five of six subjects responded, with a mean reduction in serum TXB2 of 9...

A More Expensive Aspirin?

U nstable angina is a syndrome in which the occlusion of coronary arteries by plateletdependent thrombus formation may result in myocardial infarction and death.' Angiographic2 and angioscopic3 evidence of thrombus formation is complemented by the measurement of increased concentrations of thromboxane (TX) metabolites in plasma and urine during ischemic episodes in patients with this disease.4 ...